drug
pimavanserin tartrate
Marketedupdated 5mo agoby $ACAD ACADIA PHARMACEUTICALS INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying pimavanserin tartrate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 3, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (27)
- Feb 27, 2039patentUS 10449185*PED
- Feb 27, 2039patentUS 10646480*PED
- Feb 27, 2039patentUS 10849891*PED
- Feb 27, 2039patentUS 11452721*PED
- Aug 27, 2038formulationUS 10449185
- Aug 27, 2038formulationUS 10646480
- Aug 27, 2038formulationUS 10849891
- Aug 27, 2038formulationUS 11452721
- Sep 23, 2037patentUS 10517860*PED
- Sep 23, 2037patentUS 10953000*PED
- Mar 23, 2037method-of-use (U-1974)US 10517860
- Mar 23, 2037method-of-use (U-1974)US 10953000
- Oct 29, 2030patentUS 7601740*PED4.1y
- Oct 29, 2030patentUS 7601740*PED4.1y
- Oct 29, 2030patentUS 7601740*PED4.1y
- Apr 29, 2030compositionUS 76017403.6y
- Apr 29, 2030compositionUS 76017403.6y
- Apr 29, 2030compositionUS 76017403.6y
- Dec 3, 2028patentUS 7732615*PED2.2y
- Dec 3, 2028patentUS 7732615*PED2.2y
- Dec 3, 2028patentUS 7732615*PED2.2y
- Jun 3, 2028compositionUS 77326151.7y
- Jun 3, 2028compositionUS 77326151.7y
- Jun 3, 2028compositionUS 77326151.7y
- Aug 24, 2026method-of-use (U-1844)US 7659285
- Aug 24, 2026method-of-use (U-1844)US 7659285
- Aug 24, 2026method-of-use (U-1844)US 7659285
News(1)
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…fiercebiotech · 10d ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that